Although all proximal inhibitors offer added clinical benefits in patients with persistent anemia previously treated with C5 inhibitors, pegcetacoplan is the only complement-targeted therapy approved for PNH that inhibits complement cascade activity proximally after initiation through the CP/LP and AP to provide extensive complement regulation. This evidence concerns the gene CP and paroxysmal nocturnal hemoglobinuria.